Biovail receives approval for Aplenzin for depression

April 25, 2008

News

Article

Aplenzin is a new drug from Biovail Corp. that has been approved to treat depression in adults

Aplenzin (bupropion hydrobromide), formerly known as BVF-033, is an antidepressant from Biovail Corp. that has just received approval from the Food & Drug Administration. The

Related Content

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara

November 12th 2024

Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

Looking to the Future of Independent Pharmacy

Miranda Hester

July 13th 2022

Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia

Lauren Biscaldi, MS, Managing Editor

November 5th 2024

Article

The drug is also approved to treat schizophrenia and bipolar depression.

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022

Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

FDA Expands OA REMS, Mandates Mail-Back Envelopes for Opioid Analgesics

Lauren Massaro

November 4th 2024

Article

The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.